Funding restrictions for rituximab and eltrombopag widened in New Zealand The Pharma Letter New Zealand's Pharmaceutical Management Agency PHARMAC has announced the approval of proposals to widen the restriction on rituximab use in DHB hospitals and expand the funding of eltrombopag in both hospitals and the community. This was the ... |
